During the index admission, the patients in the control group were more likely to be prescribed antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and beta-blockers compared to the patients in either of the 2 CKD groups; the phenomenon was reversed in the case of proton-pump inhibitors. The gene discussed is ACE; the disease is chronic kidney disease.